Substantial efforts have been made to produce anti-cancer therapeutics that target components of IGF-1 signaling (Table 1), which has resulted in the development of three major classes of inhibitors: anti-IGF-1R monoclonal antibodies, dual IR/IGF-1R tyrosine kinase inhibitors, and IGF neutralizing antibodies (Figure 3). The gene discussed is IGF1; the disease is cancer.